Kerecis, an Icelandic medical device company, announced two big milestones recently pertaining to the Swiss market: first, the acquisition of a Swiss life-science company, Phytoceuticals; second, the approval from Swiss healthcare authorities that the company’s lead product (Kerecis Omega3 Wound) will be reimbursed in Switzerland.
As of March 1, 2019, healthcare providers in Switzerland will be able to use Kerecis Omega3 Wound for the treatment of hard-to-heal wounds. Simultaneously, the acquisition of Phytoceuticals enables Kerecis to expand sales and operations further into the European regenerative treatment market.
Kerecis was in the news recently for partnering with MedStar Health in the US for a joint-feasibility study aimed at obtaining FDA approval for a full-fledged clinical trial.
Life science companies, such as medical device companies, incorporated in Iceland benefit from low corporate tax and encouraging financial incentives for the clinical trial R&D and commercial applications. To learn more, please visit Invest in Iceland.